沙特阿拉伯的肝癌:一个基于登记的全国性描述性流行病学和生存分析
1Department of Basic Medical Sciences, College of Medicine, Taibah University, Al-Madinah Al-Munawarah, Saudi Arabia.
Cancer epidemiology
|December 19, 2024
概括
肝癌是全球重要的健康问题. 这项研究详细介绍了沙特阿拉伯的肝癌流行病学,从2014年到2020年发现了3066例病例,主要是男性.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 肝癌是全球癌症相关死亡的主要原因之一.
- 增加的发病率凸显了流行病学研究的必要性.
- 了解区域差异对于有针对性的干预至关重要.
研究的目的:
- 描述沙特阿拉伯肝癌的流行病学.
- 分析与肝癌发病率和死亡率相关的因素.
- 为公共卫生战略和患者护理提供数据.
主要方法:
- 对肝癌患者 (2014-2020) 病历的回顾性审查.
- 利用沙特癌症登记处进行发病率数据.
- 从国际癌症研究机构 (IARC) 获得的生存数据.
主要成果:
- 在沙特国民中诊断出3066例肝癌 (2014-2020年).
- 肝细胞癌 (82.2%) 是主要的类型,其次是胆管癌 (8.7%).
- 根据年龄标准化的发病率为每10万人中4.7,死亡率为每10万人中4.6.
结论:
- 在沙特阿拉伯,肝癌对健康造成重大负担.
- 流行病学数据对于制定有效的预防和治疗策略至关重要.
- 对风险因素的进一步研究可以改善患者的治疗结果和生存率.
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups
149
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
149
Actuarial Approach
61
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
61
Introduction To Survival Analysis
180
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
180
Statistical Methods for Analyzing Epidemiological Data
299
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
299
Kaplan-Meier Approach
94
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
94


